Noramco
Noramco was a US-based, privately held CDMO specializing in active pharmaceutical ingredient (API) and controlled-substance manufacturing for global pharmaceutical and biotech companies, operating facilities in Wilmington (Delaware), Athens (Georgia), and Tasmania (Australia) under cGMP standards before its 2026 acquisition by Siegfried Holding AG.
- Company typePrivate
- Founded1979
- HeadquartersWilmington, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Noramco does
Noramco was a Delaware-incorporated, privately held contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredient (API) and drug substance production for the global pharmaceutical industry. Founded in 1979 in Wilmington, Delaware, the company operated a 150-cubic-meter reactor facility designed for commercial-scale manufacturing of innovative and controlled substances, supported by wholly-owned subsidiaries Purisys (Athens, Georgia, focused on early-phase development and custom synthesis) and Extractas Bioscience (Westbury, Tasmania, focused on alkaloid raw materials extraction). All three sites operated under cGMP API manufacturing standards with regulatory certifications enabling supply into 180+ countries and a track record of passing 100+ global inspections.
The company's core capability was integrated drug-substance manufacturing spanning custom synthesis, process development, scale-up, and GMP-compliant commercial production, with particular depth in DEA-regulated controlled substances and botanical alkaloid extraction — a relatively scarce specialization within the broader CDMO landscape. Noramco served two primary customer segments: global pharmaceutical companies requiring reliable commercial API supply and controlled-substance manufacturing capacity, and emerging biotechnology companies needing early-phase development, clinical-trial material production, and technology transfer support. GTM was enterprise field sales with direct contracts, project-based pricing, and long-term supply agreements, marketed through pharmaceutical industry conferences and direct business-development engagement rather than consumer channels.
Noramco was owned by private investment firm SK Capital Partners as part of the Noramco Group, which had been assembled through SK Capital's 2023 acquisition of Halo Pharma from Cambrex. In January 2026, SK Capital signed a definitive agreement to sell Noramco, Extractas Biosciences, and Purisys to Swiss-listed CDMO Siegfried Holding AG at a valuation multiple below 10x EV/EBITDA, completing the transaction in May 2026; SK Capital concurrently retained Halo Pharmaceuticals as a standalone drug-product CDMO. Following closing, Noramco's Wilmington facility became one of Siegfried's five "run and deliver" sites for established processes, integrated into Siegfried's 13-site global manufacturing network.
Noramco firmographics
Firmographics- Name
- Noramco
- Legal name
- Noramco, LLC
- Website
- https://noramco.com
- Company type
- Private
- Founded year
- 1979
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Noramco was a US-based, privately held CDMO specializing in active pharmaceutical ingredient (API) and controlled-substance manufacturing for global pharmaceutical and biotech companies, operating facilities in Wilmington (Delaware), Athens (Georgia), and Tasmania (Australia) under cGMP standards before its 2026 acquisition by Siegfried Holding AG.
- Ownership category
- akta.pro rank
Noramco industry classification
Industry- Product category
- Pharmaceutical API Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Noramco is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Noramco business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Noramco generated revenue through contract manufacturing of active pharmaceutical ingredients and drug substances for pharmaceutical companies. Services included custom synthesis, early-phase development, scale-up, and commercial production under cGMP standards. The business operated on a project-by-project basis with long-term supply agreements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Noramco product offering
Product offeringCore offering
Noramco is a pharmaceutical contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and drug substances for global pharmaceutical and biotechnology companies. The company operates three manufacturing sites in Wilmington (Delaware, USA), Athens (Georgia, USA), and Westbury (Tasmania, Australia), offering custom synthesis, process development, scale-up, and commercial-scale GMP manufacturing with specialization in controlled substances and alkaloid raw material extraction. Services span early-phase development through commercial production under cGMP standards with certifications to supply 180+ countries.
Product overview
Noramco was a pharmaceutical contract development and manufacturing organization (CDMO) specializing in drug substance (API) manufacturing. The company operated manufacturing facilities primarily in Wilmington, Delaware, producing active pharmaceutical ingredients and controlled substances for the pharmaceutical industry. Noramco was part of the Noramco Group, which also included Extractas Biosciences and Purisys, before the entire group was sold to Siegfried Holding AG in 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Substance (API) Contract Manufacturing Contract development and manufacturing of active pharmaceutical ingredients (APIs) and drug substances, including custom synthesis, process development, scale-up, and GMP manufacturing for global pharmaceutical companies.
- Controlled Substance API Manufacturing Specialized manufacturing services for controlled substances supporting a wide range of therapeutic applications, with strict regulatory compliance and cGMP manufacturing capabilities.
- Early-Phase Development and Custom Synthesis Process development, scale-up, and custom synthesis services supporting customers from preclinical through clinical phases, operated from the Purisys (Athens, Georgia) manufacturing site established in 1982.
- Alkaloid Raw Materials Extraction Commercial extraction of alkaloid raw materials from botanical sources, operated from the Extractas Bioscience facility in Westbury, Tasmania, Australia, established in 1975.
Companies that use Noramco
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Noramco technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Noramco partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Siegfried Holding AGcoreSiegfried Holding AG, a Swiss-listed Contract Development and Manufacturing Organization (CDMO), acquired Noramco along with Extractas Biosciences and Purisys from SK Capital Partners. The transaction encompassed three manufacturing sites with approximately 400 employees. The acquisition supports Siegfried's EVOLVE+ strategy to expand US-based manufacturing capacity and add controlled substance manufacturing expertise. Deal valued below 10x EV/EBITDA, expected to close later in 2026.
- Ensysce BiosciencesminorEnsysce Biosciences partnered with Purisys, LLC (a subsidiary of Noramco, LLC) to support manufacturing of PF614. The FDA provided positive feedback on the manufacturing approach, enabling the company to proceed towards commercial production of this pain relief drug candidate.
Scale indicators5 records
Recent moves8 records
Expansion highlights3 records
Noramco competitors and assessment
Company assessmentBroad incumbents
- Siegfried Holding AG: Swiss-listed CDMO offering both drug substance and drug product services across a 13-site network. Now Noramco's parent, but historically a direct competitor in API manufacturing with overlapping exclusive synthesis and early-phase capabilities.
- Lonza: Global CDMO leader with extensive small-molecule API capabilities across multiple sites; broader portfolio but competes with Noramco for complex API and controlled-substance work.
Direct peers
- Hovione: Privately held API CDMO specializing in complex small molecules, particle engineering, and GMP manufacturing — a direct competitor to Noramco in custom synthesis and commercial-scale API services for pharma customers.
- Cambrex: API and intermediates CDMO now part of Thermo Fisher; Noramco was carved out of Cambrex in 2023, making it a direct former-parent and current competitor in small-molecule API manufacturing.
- Johnson Matthey Health: API and fine chemicals CDMO with controlled-substance and complex-molecule capabilities; competes with Noramco in commercial-scale API supply to global pharma.
- Piramal Pharma Solutions: Integrated CDMO offering API and drug product services including controlled substances; competes with Noramco for outsourced pharma manufacturing programs.
- Alcami: US-based CDMO providing API development, manufacturing, and analytical services to pharma and biotech — a comparable scale and geographic competitor to Noramco.
Others
- Patheon (Thermo Fisher): Broadly integrated CDMO under Thermo Fisher offering API and drug product services globally; overlaps with Noramco in API supply to pharma customers.
Emerging players
- WuXi STA: Large Asian API CDMO with rapidly scaled commercial API capacity; competes with Noramco on cost for non-controlled small molecules and increasingly for global pharma contracts.
Regional players
- Aurobindo Pharma: India-based manufacturer with significant API and finished-dose capacity; while primarily a generics manufacturer, its API arm competes with Noramco for outsourced commercial-scale API supply.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Noramco social profiles
Digital presenceNoramco financial estimates
Financial estimateRevenue estimate
Valuation estimate
Noramco leadership team
Management profileNumber of profiles
Noramco subsidiaries and ownership
Company hierarchySubsidiaries2 records
Noramco funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Noramco M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Noramco
What does Noramco do?
Noramco is a pharmaceutical contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and drug substances for global pharmaceutical and biotechnology companies. The company operates three manufacturing sites in Wilmington (Delaware, USA), Athens (Georgia, USA), and Westbury (Tasmania, Australia), offering custom synthesis, process development, scale-up, and commercial-scale GMP manufacturing with specialization in controlled substances and alkaloid raw material extraction. Services span early-phase development through commercial production under cGMP standards with certifications to supply 180+ countries.
Is Noramco a public or private company?
Noramco is a private company. It is classified as corporate owned and is currently acquired.
When was Noramco founded?
Noramco was founded in 1979. It employs 251 to 500 people.
Where is Noramco based?
Noramco is headquartered in Wilmington, United States, in the North America region.
How does Noramco make money?
One revenue line is on record: contract Manufacturing Services.
Who are Noramco's main competitors?
Broad incumbents on record are Siegfried Holding AG and Lonza. Direct peers are Hovione, Cambrex, Johnson Matthey Health, Piramal Pharma Solutions and Alcami. Patheon (Thermo Fisher) is listed as an others. WuXi STA is listed as an emerging player. Aurobindo Pharma is listed as a regional player.
Does Noramco have an API?
No public API is recorded for Noramco.
What industry is Noramco in?
Noramco's product category is Pharmaceutical API Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 3254 and its SIC code is 2834.